Zacks Research Forecasts Higher Earnings for Gilead Sciences

Gilead Sciences, Inc. (NASDAQ:GILD) – Analysts at Zacks Research boosted their Q2 2026 earnings per share estimates for Gilead Sciences in a research note issued to investors on Friday, April 4th. Zacks Research analyst E. Bagri now forecasts that the biopharmaceutical company will post earnings per share of $1.84 for the quarter, up from their prior estimate of $1.83. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.95 per share. Zacks Research also issued estimates for Gilead Sciences’ Q4 2026 earnings at $2.29 EPS, FY2026 earnings at $8.02 EPS, Q1 2027 earnings at $1.88 EPS and FY2027 earnings at $8.62 EPS.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%.

GILD has been the subject of a number of other research reports. Wells Fargo & Company raised their target price on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Piper Sandler lifted their target price on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a research note on Thursday, February 13th. Royal Bank of Canada raised their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 12th. Finally, Oppenheimer boosted their target price on shares of Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a research note on Tuesday, March 4th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $105.12.

Gilead Sciences Trading Down 1.6 %

NASDAQ GILD opened at $105.52 on Monday. Gilead Sciences has a 12-month low of $62.07 and a 12-month high of $119.96. The company has a fifty day simple moving average of $107.50 and a two-hundred day simple moving average of $96.13. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The stock has a market cap of $131.39 billion, a P/E ratio of 285.19, a P/E/G ratio of 0.71 and a beta of 0.32.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.99%. The ex-dividend date of this dividend was Friday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is currently 854.05%.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders have sold 302,785 shares of company stock valued at $30,503,250. 0.16% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in GILD. Weiss Asset Management LP purchased a new stake in Gilead Sciences in the 3rd quarter valued at about $1,677,000. Kovitz Investment Group Partners LLC increased its position in shares of Gilead Sciences by 8.7% during the third quarter. Kovitz Investment Group Partners LLC now owns 97,505 shares of the biopharmaceutical company’s stock valued at $8,175,000 after acquiring an additional 7,801 shares during the last quarter. Insigneo Advisory Services LLC raised its stake in shares of Gilead Sciences by 3.0% in the 3rd quarter. Insigneo Advisory Services LLC now owns 9,096 shares of the biopharmaceutical company’s stock valued at $763,000 after acquiring an additional 266 shares during the period. EP Wealth Advisors LLC lifted its holdings in shares of Gilead Sciences by 13.7% in the 3rd quarter. EP Wealth Advisors LLC now owns 53,951 shares of the biopharmaceutical company’s stock worth $4,523,000 after acquiring an additional 6,492 shares during the last quarter. Finally, Zurich Insurance Group Ltd FI boosted its position in shares of Gilead Sciences by 791.5% during the 3rd quarter. Zurich Insurance Group Ltd FI now owns 273,685 shares of the biopharmaceutical company’s stock worth $22,946,000 after purchasing an additional 242,985 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.